|
Centre for Policy on Ageing | |
 | |
|
First among equals? does drug treatment for dementia claim more than its fair share of resources? | Author(s) | Tom Heller, Lisa Heller |
Journal title | Dementia: the international journal of social research and practice, vol 2, no 1, February 2003 |
Pages | pp 7-20 |
Keywords | Dementia ; Drugs ; Grant allocation ; Costs [care]. |
Annotation | Despite various problems associated with the introduction and use of the new generation of drugs for Alzheimer's disease (AD) - cholinesterase inhibitors - expenditure on this aspect of patient care tends to eclipse expenditure on caring and support services. Even though evidence for the effectiveness of many patient-centred approaches is increasingly available, fixed budgets for various types of services in the UK usually means that increased expenditure on medication ensures that support services will inevitably have their funding eroded. Is this the best way to provide effective care for people with dementia? The role of drug companies in this process is examined critically. (RH). |
Accession Number | CPA-030220201 A |
Classmark | EA: LLD: QCG: QDC |
Data © Centre for Policy on Ageing |
|
...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|